GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: AEGR
Buy

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) rated to Buy by Guggenheim

Monday,  Dec 21, 2015  10:25 AM ET by Betsy O'Brien Harrison

Guggenheim rated Aegerion
Pharmaceuticals, Inc. (NASDAQ: AEGR) to Buy.

Aegerion Pharmaceuticals, Inc. (Aegerion) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat severe lipid disorders. Its lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor (MTP-I), which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. The Company is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia (HoFH). HoFH is a genetic lipid disorder caused by defects in both copies of the low-density lipoprotein (LDL) receptor genes, resulting in impaired or total loss of function in the LDL receptor.

Guggenheim



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy